Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation

Inclusion Criteria: * Left ventricular ejection fraction measured by echocardiography ≥ 50% * Objective evidence of structural of functional abnormalities measured by echocardiography: 1)LVMI≥95 g/m2 in female and ≥115 g/m2 in male or 2)LAVI greater than 29ml/m2 in sinus rhythm or greater than 40ml/m2 in atrial fibrillation or 3)Average E/e' greater than 14 or 4)TR velocity greater than 2.8 m/s * Patients with elevated NT-proBNP levels 24 hours after discontinuing intravenous diuretics: ≥300 pg/ml in patients with sinus heart rate; ≥600 pg/ml in patients with atrial fibrillation * Both outpatient and admitted patients can be considered for enrollment. All patients must occurred worsening heart failure event within 30 days prior to randomization and a current NYHA cardiac function class II-IV * Patients with CRP levels greater than 2mg/L * Patient agrees to join and signs a written informed consent form Exclusion Criteria: * Received colchicine treatment within one month prior to randomization * Acute coronary syndrome within 3 months prior to randomization, or history of pacemaker implantation, PCI, CABG within 3 months * eGFR less than 25 mL/min/1.73 m2 * Liver function Child-Pugh class B or C * Patient has a history of previous allergy to colchicine or dapagliflozin / empagliflozin * Heart failure due to the following reasons: pericardial disease, pericardial effusion, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and other rare cardiomyopathies such as Fabry disease * Combined diagnosis of gastric ulcer, ulcerative colitis, Crohn disease and other digestive disorders or combined gastrointestinal tumors * Plan to undergo cardiac surgery such as coronary revascularization, radiofrequency ablation of arrhythmias, valve replacement or other surgical procedures * Pregnant or breastfeeding women * The patient who is cognitively impaired and is unable to accurately complete the assessment and completion of the KCCQ scale with the assistance of a physician * Autoimmune diseases such as systemic lupus erythematosus, long-term adrenocorticotropic hormone treatment for other diseases such as Schihan syndrome, or need to accept immunosuppressive drugs and monoclonal antibodies such as IL-1 and IL-6 * Patient with combined active solid tumor or hematological malignancy * Patient comorbidity with other conditions that may be confused with HFpEF symptoms, such as acute exacerbation of COPD * Admission with a well-defined infection (symptoms or pathogenetic evidence of infection, and leukocytes greater than 10\*109/L) * Previously diagnosed with HFrEF (initial assessment of LVEF less than 40%) or diagnosed with LVimpEF